Stem cell transplantation for the treatment of diabetic foot

Wang Guang-yu,Zhu Lü-yun,Ma Li-cheng,Hu Li-ye,Li Xiao-ling,Yang Shao-ling,Shan Wei,Hou Rong-rong
DOI: https://doi.org/10.3969/j.issn.2095-4344.2013.01.028
2013-01-01
Abstract:BACKGROUND: Autologous bone marrow and umbilical blood mononuclear cell transplantation can improve the clinical symptoms caused by ischemic lesions and peripheral nerve injury, and have good effect on diabetic foot. Umbilical cord-derived mesenchymal stem cells have their own advantages when compared with bone marrow stem cells and umbilical cord blood stem cells.OBJECTIVE: To observe the effect of umbilical cord-derived mesenchymal stem cells on diabetic foot ischemic lesions and peripheral nerve injury. METHODS: Thirty-two patients with diabetic foot who received umbilical cord-derived mesenchymal stem cell transplantation from 2010 to 2012 were selected. Umbilical cord-derived mesenchymal stem cells were intramuscularly injected into the bilateral lower extremities with 3 cm distance between two injection sites after dilution. The number of implanted cells was (5.02±1.37) ×10 8 per leg. The lower extremity ischemia and lower extremity peripheral neuropathy were evaluated at 3 and 6 months after injection. The CMKI database was searched for the literatures in order to analyze the research situation of stem cell transplantation for the treatment of diabetic foot in China. RESULTS AND CONCLUSION: There was no significant difference in ankle/brachial index after treatment. The pain score and the apathetic score were significantly improved at 6 months after transplantation. There were significant differences in angina cruris, skin temperature and transcutaneous oxygen partial pressure after 3 or 6 months of treatment. After treatment for 6 months, there were significant differences in rational symptom score, clinical examination score and vibration perception threshold. There were no significant differences in the conduction velocity of motor/sensory nerves of peroneal nerve and tibial nerve at 3 months after transplantation when compared with those before transplantation (P > 0.05), and there were significant differences at 6 months after transplantation when compared with those before transplantation (P < 0.05). The clinical symptoms and objective indexes of diabetic ischemic lesions and peripheral neuropathy can be improved by umbilical cord- derived mesenchymal stem cells. Literatures analysis has shown that the therapeutic effect in the existing research is satisfactory, and the transplantation method in most researches is consistent with that in this research.
What problem does this paper attempt to address?